Table 1. PD-L1 testing on EBUS-TBNA specimens: feasibility and concordance with histology samples.
| Author, year | PD-L1 assay | TPS cut-offs | Number of EBUS-TBNA samples | Feasibility of PD-L1 testing | Number and type of paired samples | Agreement analysis | Comments |
|---|---|---|---|---|---|---|---|
| Sakakibara 2017 (47) | EPR1161 | N/A | EBUS-TBNA 97 | 99% | Resected primary tumor 6, resected LN 5, TBB 16 | Pearson correlation for lung resection r=0.75, for LN metastasis r=0.93, for TBB r=0.75 | 1 of 97 EBUS-TBNA sample had <100 tumor cells |
| Sakata 2018 (48) | 22C3 | ≥1%, ≥50% | EBUS-TBNA 61 | 84% | Surgical resection 61 | Concordance 87% for cut-off ≥1% and 82% for cut-off ≥50% | – |
| Wang 2019 (49) | 22C3 | ≥50% | EBUS-TBNA | 86.8% | Paired surgical biopsy 34 | Concordance 91.3% | – |
| Smith 2019 (50) | 22C3 | ≥50% | EBUS-TBNA | 92% | Surgical resection 11, TBB 1, core biopsies 4, pleural biopsy 1, autopsy 1 | Concordance 78% | – |
| Stoy 2018 (51) | 28-8 | <1%, 1–49%, ≥50% | EBUS-TBNA 16, endobronchial FNA 4, peripheral TBNA nodule 2 | 88% for 16 EBUS-TBNA samples | FOB biopsy 2 (same location), 1 (different location) | Concordance in 2 of 3 cases (for which cytology and histology were from same location) | – |
| Biswas 2018 (52) | 22C3 | <1%, 1–49%, ≥50% | EBUS-TBNA 50 | 86% | N/A | N/A | – |
| Fernandez-Bussy 2018 (53) | E1L3N | <1%, 1–50%, >50% | EBUS-TBNA 23 | 100% | N/A | N/A | – |
Table adapted with permission from Smith et al. (50). PD-L1, programmed death-ligand 1; CT, computed tomography; EBUS-TBNA, endobronchial ultrasound with transbronchial needle aspiration; FNA, fine needle aspiration; FOB, flexible bronchoscopy; LN, lymph node; N/A, not available; TBB, transbronchial biopsy.